UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000021110
Receipt number R000024120
Scientific Title Efficacy and safety of administration of Tolvaptan twice daily in hospitalized acute heart failure patients
Date of disclosure of the study information 2016/02/19
Last modified on 2018/04/21 13:53:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and safety of administration of Tolvaptan twice daily in hospitalized acute heart failure patients

Acronym

Administration of Tolvaptan twice daily in hospitalized acute heart failure patients

Scientific Title

Efficacy and safety of administration of Tolvaptan twice daily in hospitalized acute heart failure patients

Scientific Title:Acronym

Administration of Tolvaptan twice daily in hospitalized acute heart failure patients

Region

Japan


Condition

Condition

acute heart failure

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Comparison of efficacy and adverse effect of Tolvaptan between administration twice daily and that of once daily in patients with acute heart failure

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

change of congestion scale (7 consecutive days from administration)

Key secondary outcomes

serial change of renal function (7 consecutive days after administration)
urine volume (7 consecutive days after administration)
weight change (7 consecutive days after administration)
serial change of other laboratory markers(7 consecutive days after administration)
prognosis(30-day, 6-month)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administrations of Tolvaptan once daily at 9 AM (Duration of administration or total dose of Tolvaptan is determined by clinical course)

Interventions/Control_2

Administrations of Tolvaptan twice daily at 9 AM and 3 PM (Duration of administration or total dose of Tolvaptan is determined by clinical course)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Hospitalized acute heart failure patients with volume overload
Subjects with NYHA functional classification II-IV
Subjects with Furosemide > 40mg/day
Serum sodium level < 140mEq/L
Agreement with written informed consent

Key exclusion criteria

Subjects with hemodialysis or anuria
Subjects with acute coronary syndrome, pregnancy, malignancy, or previously administration of Tolvaptan

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Haruo Kamiya

Organization

Japanese Red Cross Nagoya First Hospital

Division name

Department of Cardiology

Zip code


Address

3-35, Michishita-cho, Nakamura-ku, Nagoya city, Aichi, Japan

TEL

052-481-5111

Email

oguricap0909@gmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Mitsutoshi Oguri

Organization

Kasugai Municipal Hospital

Division name

Department of Cardiology

Zip code


Address

1-1-1 Takaki-cho, Kasugai Aichi 486-8510, Japan

TEL

0568-57-0057

Homepage URL


Email

oguricap0909@gmail.com


Sponsor or person

Institute

Japanese Red Cross Nagoya First Hospital

Institute

Department

Personal name



Funding Source

Organization

Kasugai Municipal Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Kasugai Municipal Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 02 Month 19 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

The subjects were assigned to either the once-daily 7.5mg dosing regimen (N=15) or the twice-daily 3.75mg dosing regimen (N=16). The time-course changes in body weight, serum sodium and creatinine levels, systolic blood pressure, daily urine output, and congestion scores were similar between the two groups. In the twice-daily 3.75mg dosing group, the serum sodium levels on days 3 and 4 were significantly (p<0.05) increased compared with those on day 1. The congestion scores significantly (p<0.05) decreased from day 2 to day 7 in both groups compared with those on day 1. However, the difference in the serial change in the congestion scores did not reach statistical significance.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 10 Month 18 Day

Date of IRB


Anticipated trial start date

2016 Year 02 Month 19 Day

Last follow-up date


Date of closure to data entry

2017 Year 06 Month 30 Day

Date trial data considered complete

2017 Year 06 Month 30 Day

Date analysis concluded



Other

Other related information

J Cardiol. 2018 Mar 19. pii: S0914-5087(18)30052-2. doi: 10.1016/j.jjcc.2018.02.006.


Management information

Registered date

2016 Year 02 Month 19 Day

Last modified on

2018 Year 04 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024120


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name